

Philip Tedbury

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1509907/philip-tedbury-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123
papers

4,562
citations

36
h-index

63
g-index

133
ext. papers

5,342
ext. citations

7.8
avg, IF

5.49
L-index

#	Paper	IF	Citations
123	Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. <i>EMBO Journal</i> , 2001 , 20, 1449-61	13	360
122	Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. <i>Journal of Molecular Biology</i> , 2009 , 385, 693-713	6.5	355
121	Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. <i>Journal of Molecular Biology</i> , 1998 , 284, 1095-111	6.5	302
120	Biochemistry and cell biology of mammalian scavenger receptors. <i>Atherosclerosis</i> , 2005 , 182, 1-15	3.1	273
119	Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. <i>EMBO Journal</i> , 2002 , 21, 6614-24	13	167
118	STRUCTURAL VIROLOGY. X-ray crystal structures of native HIV-1 capsid protein reveal conformational variability. <i>Science</i> , 2015 , 349, 99-103	33.3	156
117	Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 11549-54	11.5	109
116	Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-ethynyl-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. <i>Journal of Biological Chemistry</i> , 2009 , 284, 35681-91	5.4	104
115	Capsid-CPSF6 Interaction Licenses Nuclear HIV-1 Trafficking to Sites of Viral DNA Integration. <i>Cell Host and Microbe</i> , 2018 , 24, 392-404.e8	23.4	96
114	2'-deoxy-4'-C-ethynyl-2'-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. <i>International Journal of Biochemistry and Cell Biology</i> , 2008 , 40, 2410-20	5.6	90
113	The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. <i>PLoS Pathogens</i> , 2013 , 9, e1003125	7.6	85
112	The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. <i>Journal of Virology</i> , 2002 , 76, 3248-56	6.6	81
111	Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4894-8	5.9	80
110	Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4718-28	5.9	72
109	LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells. <i>Biochemical Journal</i> , 2006 , 393, 107-15	3.8	67
108	Trapping HIV-1 reverse transcriptase before and after translocation on DNA. <i>Journal of Biological Chemistry</i> , 2003 , 278, 16280-8	5.4	66
107	Antiviral drugs specific for coronaviruses in preclinical development. <i>Current Opinion in Virology</i> , 2014 , 8, 45-53	7.5	64

106	Oral administration of the nucleoside EFdA (4-Ethynyl-2-fluoro-2-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4190-8	5.9	61
105	4-Ethynyl-2-fluoro-2-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. <i>Journal of Biological Chemistry</i> , 2014 , 289, 24533-48	5.4	58
104	Structural and Molecular Determinants of Membrane Binding by the HIV-1 Matrix Protein. <i>Journal of Molecular Biology</i> , 2016 , 428, 1637-55	6.5	55
103	Global rescue of defects in HIV-1 envelope glycoprotein incorporation: implications for matrix structure. <i>PLoS Pathogens</i> , 2013 , 9, e1003739	7.6	54
102	4-Ethynyl-2-fluoro-2-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor. <i>Current Opinion in HIV and AIDS</i> , 2018 , 13, 294-299	4.2	53
101	Structural basis of HIV inhibition by translocation-defective RT inhibitor 4-Ethynyl-2-fluoro-2-deoxyadenosine (EFdA). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 9274-9	11.5	53
100	Biochemical mechanism of HIV-1 resistance to rilpivirine. <i>Journal of Biological Chemistry</i> , 2012 , 287, 38110-23	4.23	51
99	Hepatitis C virus-induced autophagy is independent of the unfolded protein response. <i>Journal of Virology</i> , 2012 , 86, 10724-32	6.6	48
98	HIV-1 replication complexes accumulate in nuclear speckles and integrate into speckle-associated genomic domains. <i>Nature Communications</i> , 2020 , 11, 3505	17.4	48
97	Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. <i>Journal of Virology</i> , 2003 , 77, 8548-54	6.6	47
96	Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4-Ethynyl-2-fluoro-2-deoxyadenosine in vitro and in vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4707-12	5.9	44
95	The role of matrix in HIV-1 envelope glycoprotein incorporation. <i>Trends in Microbiology</i> , 2014 , 22, 372-8	12.4	42
94	Design, Synthesis, and Biological Evaluations of Hydroxypyridonecarboxylic Acids as Inhibitors of HIV Reverse Transcriptase Associated RNase H. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 5051-62	8.3	42
93	Biochemical evidence of a role for matrix trimerization in HIV-1 envelope glycoprotein incorporation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E182-90	11.5	41
92	The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine. <i>Journal of Biological Chemistry</i> , 2010 , 285, 38700-9	5.4	39
91	Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs. <i>International Journal of Biochemistry and Cell Biology</i> , 2004 , 36, 1706-15	5.6	39
90	Multiplex single-cell visualization of nucleic acids and protein during HIV infection. <i>Nature Communications</i> , 2017 , 8, 1882	17.4	37
89	The subcellular localization of the hepatitis C virus non-structural protein NS2 is regulated by an ion channel-independent function of the p7 protein. <i>Journal of General Virology</i> , 2011 , 92, 819-30	4.9	37

88	4Vmodified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus. <i>Hepatology</i> , 2015 , 62, 1024-36	11.2	36
87	Antiviral therapies: focus on hepatitis B reverse transcriptase. <i>International Journal of Biochemistry and Cell Biology</i> , 2012 , 44, 1060-71	5.6	34
86	Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 1125-1137	8.3	32
85	3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 6136-48	8.3	31
84	3-Hydroxypyrimidine-2,4-diones as Selective Active Site Inhibitors of HIV Reverse Transcriptase-Associated RNase H: Design, Synthesis, and Biochemical Evaluations. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 2648-59	8.3	31
83	The Use of Minimal RNA Toeholds to Trigger the Activation of Multiple Functionalities. <i>Nano Letters</i> , 2016 , 16, 1746-53	11.5	31
82	Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. <i>Retrovirology</i> , 2013 , 10, 65	3.6	30
81	Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H. <i>European Journal of Medicinal Chemistry</i> , 2017 , 141, 149-161	6.8	28
80	Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor. <i>International Journal of Pharmaceutics</i> , 2014 , 461, 203-13	6.5	28
79	Effects of substitutions at the 4Vand 2 positions on the bioactivity of 4Vethynyl-2-fluoro-2Vdeoxyadenosine. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 6254-64	5.9	28
78	Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 5045-5056	8.3	27
77	Structural and inhibition studies of the RNase H function of xenotropic murine leukemia virus-related virus reverse transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 2048-61	5.9	27
76	Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase. <i>Microorganisms</i> , 2021 , 9,	4.9	27
75	Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. <i>Scientific Reports</i> , 2017 , 7, 43908	4.9	25
74	Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase. <i>Pharmaceutics</i> , 2019 , 12,	5.2	25
73	Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs. <i>Pathogens</i> , 2020 , 9,	4.5	22
72	Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors. <i>Viruses</i> , 2014 , 6, 3535-62	6.2	22
71	SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4915-9	5.9	21

70	Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine indicates a low potential for host toxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 1630-4	5.9	21
69	Characterisation of the role of zinc in the hepatitis C virus NS2/3 auto-cleavage and NS3 protease activities. <i>Journal of Molecular Biology</i> , 2007 , 366, 1652-60	6.5	21
68	Identification using phage display of peptides promoting targeting and internalization into HPV-transformed cell lines. <i>Journal of Molecular Recognition</i> , 2005 , 18, 175-82	2.6	21
67	Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 3482-92	5.9	19
66	Glycosylated diphyllin as a broad-spectrum antiviral agent against Zika virus. <i>EBioMedicine</i> , 2019 , 47, 269-283	8.8	18
65	HIV-1 gag: an emerging target for antiretroviral therapy. <i>Current Topics in Microbiology and Immunology</i> , 2015 , 389, 171-201	3.3	18
64	6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H. <i>European Journal of Medicinal Chemistry</i> , 2018 , 156, 680-691	6.8	18
63	Avoiding Drug Resistance in HIV Reverse Transcriptase. <i>Chemical Reviews</i> , 2021 , 121, 3271-3296	68.1	18
62	Multifunctionality of a picornavirus polymerase domain: nuclear localization signal and nucleotide recognition. <i>Journal of Virology</i> , 2015 , 89, 6848-59	6.6	17
61	Elucidating the mechanism by which compensatory mutations rescue an HIV-1 matrix mutant defective for gag membrane targeting and envelope glycoprotein incorporation. <i>Journal of Molecular Biology</i> , 2015 , 427, 1413-1427	6.5	17
60	Cutting into the Substrate Dominance: Pharmacophore and Structure-Based Approaches toward Inhibiting Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H. <i>Accounts of Chemical Research</i> , 2020 , 53, 218-230	24.3	17
59	The cytoplasmic tail of retroviral envelope glycoproteins. <i>Progress in Molecular Biology and Translational Science</i> , 2015 , 129, 253-84	4	16
58	Evaluation of Combinations of 4'-ethynyl-2-fluoro-2'-deoxyadenosine with Clinically Used Antiretroviral Drugs. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 4554-4558	5.9	16
57	Trimer Enhancement Mutation Effects on HIV-1 Matrix Protein Binding Activities. <i>Journal of Virology</i> , 2016 , 90, 5657-5664	6.6	16
56	The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase. <i>Cell Chemical Biology</i> , 2018 , 25, 1268-1278.e3	8.2	16
55	Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	15
54	Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase. <i>European Journal of Medicinal Chemistry</i> , 2017 , 133, 85-96	6.8	15
53	Analysis of HIV-1 Matrix-Envelope Cytoplasmic Tail Interactions. <i>Journal of Virology</i> , 2019 , 93,	6.6	15

52	6-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverse transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase. <i>European Journal of Medicinal Chemistry</i> , 2017 , 128, 168-179	6.8	14
51	6-Arylthio-3-hydroxypyrimidine-2,4-diones potently inhibited HIV reverse transcriptase-associated RNase H with antiviral activity. <i>European Journal of Medicinal Chemistry</i> , 2018 , 156, 652-665	6.8	14
50	Probing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4Vethynyl-2-fluoro-2Vdeoxyadenosine (EFdA) using pre-steady-state kinetics. <i>Antiviral Research</i> , 2014 , 106, 1-4	10.8	14
49	In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers. <i>European Journal of Pharmacology</i> , 2014 , 732, 86-95	5.3	13
48	Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase. <i>Nucleic Acids Research</i> , 2012 , 40, 345-59	20.1	13
47	3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	12
46	Toward Structurally Novel and Metabolically Stable HIV-1 Capsid-Targeting Small Molecules. <i>Viruses</i> , 2020 , 12,	6.2	12
45	The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells. <i>MSphere</i> , 2018 , 3,	5	12
44	HIV-1 Matrix Trimerization-Impaired Mutants Are Rescued by Matrix Substitutions That Enhance Envelope Glycoprotein Incorporation. <i>Journal of Virology</i> , 2019 , 94,	6.6	12
43	Chemical profiling of HIV-1 capsid-targeting antiviral PF74. <i>European Journal of Medicinal Chemistry</i> , 2020 , 200, 112427	6.8	12
42	The SMC5/6 complex compacts and silences unintegrated HIV-1 DNA and is antagonized by Vpr. <i>Cell Host and Microbe</i> , 2021 , 29, 792-805.e6	23.4	12
41	CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	11
40	Novel Intersubunit Interaction Critical for HIV-1 Core Assembly Defines a Potentially Targetable Inhibitor Binding Pocket. <i>MBio</i> , 2019 , 10,	7.8	11
39	Pharmacophore-based design of novel 3-hydroxypyrimidine-2,4-dione subtypes as inhibitors of HIV reverse transcriptase-associated RNase H: Tolerance of a nonflexible linker. <i>European Journal of Medicinal Chemistry</i> , 2019 , 166, 390-399	6.8	11
38	Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes. <i>Frontiers in Microbiology</i> , 2018 , 9, 1754	5.7	11
37	A 2-Hydroxyisoquinoline-1,3-Dione Active-Site RNase H Inhibitor Binds in Multiple Modes to HIV-1 Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	11
36	5-Aminothiophene-2,4-dicarboxamide analogues as hepatitis B virus capsid assembly effectors. <i>European Journal of Medicinal Chemistry</i> , 2019 , 164, 179-192	6.8	11
35	Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa. <i>Journal of Medical Virology</i> , 2017 , 89, 106-111	19.7	10

34	Molecular and Functional Bases of Selection against a Mutation Bias in an RNA Virus. <i>Genome Biology and Evolution</i> , 2017 , 9, 1212-1228	3.9	10
33	Antiretroviral potency of 4Vethnyl-2Vfluoro-2Vdeoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2721-2728	5.1	10
32	Novel HIV-1 capsid-targeting small molecules of the PF74 binding site. <i>European Journal of Medicinal Chemistry</i> , 2020 , 204, 112626	6.8	10
31	Novel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores. <i>ACS Infectious Diseases</i> , 2019 , 5, 750-758	5.5	8
30	Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation. <i>MBio</i> , 2018 , 9,	7.8	8
29	Novel PF74-like small molecules targeting the HIV-1 capsid protein: Balance of potency and metabolic stability. <i>Acta Pharmaceutica Sinica B</i> , 2021 , 11, 810-822	15.5	7
28	Determinants of Active-Site Inhibitor Interaction with HIV-1 RNase H. <i>ACS Infectious Diseases</i> , 2019 , 5, 1963-1974	5.5	6
27	Strain-specific effect on biphasic DNA binding by HIV-1 integrase. <i>Aids</i> , 2019 , 33, 588-592	3.5	6
26	7-Deaza-7-fluoro modification confers on 4Vcyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety. <i>Antiviral Research</i> , 2020 , 176, 104744	10.8	6
25	Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 367-71	5.1	6
24	A comparative analysis of the fluorescence properties of the wild-type and active site mutants of the hepatitis C virus autoprotease NS2-3. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2010 , 1804, 212-22	4	6
23	Visualization of HIV-1 RNA Transcription from Integrated HIV-1 DNA in Reactivated Latently Infected Cells. <i>Viruses</i> , 2018 , 10,	6.2	6
22	Effect of tRNA on the Maturation of HIV-1 Reverse Transcriptase. <i>Journal of Molecular Biology</i> , 2018 , 430, 1891-1900	6.5	5
21	Effects of Moloney Leukemia Virus 10 Protein on Hepatitis B Virus Infection and Viral Replication. <i>Viruses</i> , 2019 , 11,	6.2	5
20	Design, Synthesis and Characterization of HIV-1 CA-Targeting Small Molecules: Conformational Restriction of PF74. <i>Viruses</i> , 2021 , 13,	6.2	5
19	Molecular Dynamics Free Energy Simulations Reveal the Mechanism for the Antiviral Resistance of the M66I HIV-1 Capsid Mutation. <i>Viruses</i> , 2021 , 13,	6.2	5
18	Visualization of Positive and Negative Sense Viral RNA for Probing the Mechanism of Direct-Acting Antivirals against Hepatitis C Virus. <i>Viruses</i> , 2019 , 11,	6.2	5
17	Rotten to the core: antivirals targeting the HIV-1 capsid core.. <i>Retrovirology</i> , 2021 , 18, 41	3.6	5

16	Effect of P-body component Mov10 on HCV virus production and infectivity. <i>FASEB Journal</i> , 2020 , 34, 9433-9449	0.9	4
15	Discovery of New Small Molecule Hits as Hepatitis B Virus Capsid Assembly Modulators: Structure and Pharmacophore-Based Approaches. <i>Viruses</i> , 2021 , 13,	6.2	4
14	Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021 , 2, 100045	3	4
13	Conformational Changes in HIV-1 Reverse Transcriptase that Facilitate Its Maturation. <i>Structure</i> , 2019 , 27, 1581-1593.e3	5.2	3
12	Contribution of a Multifunctional Polymerase Region of Foot-and-Mouth Disease Virus to Lethal Mutagenesis. <i>Journal of Virology</i> , 2018 , 92,	6.6	3
11	Exposing HIV's weaknesses. <i>Journal of Biological Chemistry</i> , 2017 , 292, 6027-6028	5.4	2
10	Elucidating the Basis for Permissivity of the MT-4 T-Cell Line to Replication of an HIV-1 Mutant Lacking the gp41 Cytoplasmic Tail. <i>Journal of Virology</i> , 2020 , 94,	6.6	2
9	Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethenyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0116721	5.9	2
8	Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247. <i>FASEB Journal</i> , 2015 , 29, 70-80	0.9	1
7	Biochemistry. RT slides home. <i>Science</i> , 2008 , 322, 1059-60	33.3	1
6	Structure-based virtual screening workflow to identify antivirals targeting HIV-1 capsid.. <i>Journal of Computer-Aided Molecular Design</i> , 2022 , 36, 193	4.2	1
5	Potency and metabolic stability: a molecular hybrid case in the design of novel PF74-like small molecules targeting HIV-1 capsid protein.. <i>RSC Medicinal Chemistry</i> , 2021 , 12, 2031-2044	3.5	0
4	Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations. <i>Viruses</i> , 2022 , 14, 1202	6.2	0
3	Structures of Wild-Type and AZT-Resistant HIV-1 Reverse Transcriptase Complexed with AZTppppA Yield Insights into the Nucleotide Excision Mechanism. <i>FASEB Journal</i> , 2007 , 21, A640	0.9	
2	Hepatitis C Virus 2009 , 47-69		
1	Virus Assembly 2013 , 1-11		